{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:45:48Z","timestamp":1794649548541,"version":"4.9.1"},"reference-count":62,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"n\/a","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Reducing casein kinase 1\u03b1 (CK1\u03b1) expression inhibits the growth of multiple cancer cell lines, making it a potential therapeutic target for cancer. Herein, we evaluated the antitumor activity of FPFT-2216\u2014a novel low molecular weight compound\u2014in lymphoid tumors and elucidated its molecular mechanism of action. In addition, we determined whether targeting CK1\u03b1 with FPFT-2216 is useful for treating hematopoietic malignancies. FPFT-2216 strongly degraded CK1\u03b1 and IKAROS family zinc finger 1\/3 (IKZF1\/3) via proteasomal degradation. FPFT-2216 exhibited stronger inhibitory effects on human lymphoma cell proliferation than known thalidomide derivatives and induced upregulation of p53 and its transcriptional targets, namely, p21 and MDM2. Combining FPFT-2216 with an MDM2 inhibitor exhibited synergistic antiproliferative activity and induced rapid tumor regression in immunodeficient mice subcutaneously transplanted with a human lymphoma cell line. Nearly all tumors in mice disappeared after 10 days; this was continuously observed in 5 of 7 mice up to 24 days after the final FPFT-2216 administration. FPFT-2216 also enhanced the antitumor activity of rituximab and showed antitumor activity in a patient-derived diffuse large B-cell lymphoma xenograft model. Furthermore, FPFT-2216 decreased the activity of the CARD11\/BCL10\/MALT1 (CBM) complex and inhibited I\u03baB\u03b1 and NF\u03baB phosphorylation. These effects were mediated through CK1\u03b1 degradation and were stronger than those of known IKZF1\/3 degraders. In conclusion, FPFT-2216 inhibits tumor growth by activating the p53 signaling pathway and inhibiting the CBM complex\/NF\u03baB pathway via CK1\u03b1 degradation. Therefore, FPFT-2216 may represent an effective therapeutic agent for hematopoietic malignancies, such as lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We found potential vulnerability to CK1\u03b1 degradation in certain lymphoma cells refractory to IKZF1\/3 degraders. Targeting CK1\u03b1 with FPFT-2216 could inhibit the growth of these cells by activating p53 signaling. Our study demonstrates the potential therapeutic application of CK1\u03b1 degraders, such as FPFT-2216, for treating lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0264","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T09:12:55Z","timestamp":1706087575000},"page":"312-327","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1\/3 and CK1\u03b1 to Activate p53 and Inhibit NF\u03baB Signaling"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0696-062X","authenticated-orcid":true,"given":"Daiki","family":"Kanaoka","sequence":"first","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6940-8129","authenticated-orcid":true,"given":"Mitsuo","family":"Yamada","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7366-9309","authenticated-orcid":true,"given":"Hironori","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2729-984X","authenticated-orcid":true,"given":"Satoko","family":"Nishino","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8572-1729","authenticated-orcid":true,"given":"Naoshi","family":"Kunimura","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8120-2271","authenticated-orcid":true,"given":"Hiroshi","family":"Satoyoshi","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4495-954X","authenticated-orcid":true,"given":"Shota","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4917-0297","authenticated-orcid":true,"given":"Kazunori","family":"Urabe","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0167-3228","authenticated-orcid":true,"given":"Takafumi","family":"Ishii","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1875-6617","authenticated-orcid":true,"given":"Masato","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"2024020614011291800_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1078155220975825","article-title":"A drug repositioning success: the repositioned therapeutic applications and mechanisms of action of thalidomide","volume":"27","author":"Amare","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2024020614011291800_bib2","doi-asserted-by":"crossref","first-page":"110114","DOI":"10.1016\/j.biopha.2020.110114","article-title":"Recent advances in the molecular mechanism of thalidomide teratogenicity","volume":"127","author":"Gao","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2024020614011291800_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5045\/br.2022.2022001","article-title":"Update on the POEMS syndrome","volume":"57","author":"Kim","year":"2022","journal-title":"Blood Res"},{"key":"2024020614011291800_bib4","doi-asserted-by":"crossref","first-page":"100994","DOI":"10.1016\/j.blre.2022.100994","article-title":"Targeting cereblon in hematologic malignancies","volume":"57","author":"Fuchs","year":"2022","journal-title":"Blood Rev"},{"key":"2024020614011291800_bib5","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.3390\/ijms22168572","article-title":"Immunomodulatory drugs for the treatment of B cell malignancies","volume":"22","author":"Ioannou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024020614011291800_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"2024020614011291800_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"2024020614011291800_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"2024020614011291800_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"2024020614011291800_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"2024020614011291800_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/acs.jmedchem.1c01832","article-title":"Development of PDE6D and CK1\u03b1 degraders through chemical derivatization of FPFT-2216","volume":"65","author":"Teng","year":"2022","journal-title":"J Med Chem"},{"key":"2024020614011291800_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-018-0236-z","article-title":"Casein kinase 1\u03b1: biological mechanisms and theranostic potential","volume":"16","author":"Jiang","year":"2018","journal-title":"Cell Commun Signal"},{"key":"2024020614011291800_bib13","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.3390\/ijms21239026","article-title":"Targeting casein kinase 1 (CK1) in hematological cancers","volume":"21","author":"Janovsk\u00e1","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024020614011291800_bib14","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.3390\/ijms22073716","article-title":"Targeting protein kinases in blood cancer: focusing on CK1\u03b1 and CK2","volume":"22","author":"Spinello","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024020614011291800_bib15","doi-asserted-by":"crossref","first-page":"32384","DOI":"10.1074\/jbc.M109.052647","article-title":"CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability","volume":"284","author":"Huart","year":"2009","journal-title":"J Biol Chem"},{"key":"2024020614011291800_bib16","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1128\/MCB.25.15.6509-6520.2005","article-title":"Regulation of p53-MDMX interaction by casein kinase 1 alpha","volume":"25","author":"Chen","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2024020614011291800_bib17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1084\/jem.20131033","article-title":"Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia","volume":"211","author":"J\u00e4r\u00e5s","year":"2014","journal-title":"J Exp Med"},{"key":"2024020614011291800_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","article-title":"Small molecules co-targeting CKI\u03b1 and the transcriptional kinases CDK7\/9 control AML in preclinical models","volume":"175","author":"Minzel","year":"2018","journal-title":"Cell"},{"key":"2024020614011291800_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature07613","article-title":"Casein kinase 1\u03b1 governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival","volume":"458","author":"Bid\u00e8re","year":"2009","journal-title":"Nature"},{"key":"2024020614011291800_bib20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.celrep.2019.09.040","article-title":"MALT1 phosphorylation controls activation of T lymphocytes and survival of ABC-DLBCL tumor cells","volume":"29","author":"Gehring","year":"2019","journal-title":"Cell Rep"},{"key":"2024020614011291800_bib21","doi-asserted-by":"crossref","first-page":"733848","DOI":"10.3389\/fonc.2021.733848","article-title":"Protein kinase CK1\u03b1 sustains B-cell receptor signaling in mantle cell lymphoma","volume":"11","author":"Manni","year":"2021","journal-title":"Front Oncol"},{"key":"2024020614011291800_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"key":"2024020614011291800_bib23","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.1814446115","article-title":"Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs","volume":"115","author":"Gemechu","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024020614011291800_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/2643-3230.BCD-20-0105","article-title":"Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies","volume":"2","author":"Renneville","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2024020614011291800_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-01-828418","article-title":"CK1\u03b1 and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma","volume":"132","author":"Patil","year":"2018","journal-title":"Blood"},{"key":"2024020614011291800_bib26","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1038\/s41467-021-25634-z","article-title":"The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling","volume":"12","author":"Shen","year":"2021","journal-title":"Nat Commun"},{"key":"2024020614011291800_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4(CRBN) ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"2024020614011291800_bib28","doi-asserted-by":"crossref","first-page":"102227","DOI":"10.1016\/j.jbc.2022.102227","article-title":"The casein kinase 1\u03b1 agonist pyrvinium attenuates Wnt-mediated CK1\u03b1 degradation via interaction with the E3 ubiquitin ligase component Cereblon","volume":"298","author":"Shen","year":"2022","journal-title":"J Biol Chem"},{"key":"2024020614011291800_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/ejh.12756","article-title":"Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)","volume":"97","author":"Herting","year":"2016","journal-title":"Eur J Haematol"},{"key":"2024020614011291800_bib30","doi-asserted-by":"crossref","first-page":"18094","DOI":"10.18632\/oncotarget.4093","article-title":"rRNA synthesis inhibitor, CX-5461, activates ATM\/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis","volume":"6","author":"Negi","year":"2015","journal-title":"Oncotarget"},{"key":"2024020614011291800_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","article-title":"Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma","volume":"21","author":"Trabucco","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2024020614011291800_bib32","doi-asserted-by":"crossref","first-page":"14912","DOI":"10.18632\/oncotarget.14741","article-title":"Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"key":"2024020614011291800_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41419-021-03695-8","article-title":"Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma","volume":"12","author":"Nie","year":"2021","journal-title":"Cell Death Dis"},{"key":"2024020614011291800_bib34","doi-asserted-by":"crossref","first-page":"114334","DOI":"10.1016\/j.ejmech.2022.114334","article-title":"Small-molecule MDM2 inhibitors in clinical trials for cancer therapy","volume":"236","author":"Wang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2024020614011291800_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-016-0280-3","article-title":"Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models","volume":"9","author":"Lehmann","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2024020614011291800_bib36","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"key":"2024020614011291800_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature04687","article-title":"A loss-of-function RNA interference screen for molecular targets in cancer","volume":"441","author":"Ngo","year":"2006","journal-title":"Nature"},{"key":"2024020614011291800_bib38","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1172\/JCI99436","article-title":"Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth","volume":"128","author":"Font\u00e1n","year":"2018","journal-title":"J Clin Invest"},{"key":"2024020614011291800_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/10428194.2013.806799","article-title":"Bortezomib inhibits proteasomal degradation of I\u03baB\u03b1 and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma","volume":"55","author":"Bu","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2024020614011291800_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-023-00809-7","article-title":"MALT1-dependent cleavage of CYLD promotes NF-\u03baB signaling and growth of aggressive B-cell receptor-dependent lymphomas","volume":"13","author":"Minderman","year":"2023","journal-title":"Blood Cancer J"},{"key":"2024020614011291800_bib41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"2024020614011291800_bib42","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/annrheumdis-2017-212916","article-title":"Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","volume":"77","author":"Schafer","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024020614011291800_bib43","doi-asserted-by":"crossref","first-page":"2040620719898373","DOI":"10.1177\/2040620719898373","article-title":"WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma","volume":"11","author":"de Jong","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"2024020614011291800_bib44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s13577-020-00347-5","article-title":"Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations","volume":"33","author":"Kasai","year":"2020","journal-title":"Hum Cell"},{"key":"2024020614011291800_bib45","doi-asserted-by":"crossref","first-page":"e43391","DOI":"10.1371\/journal.pone.0043391","article-title":"Exploiting the MDM2-CK1\u03b1 protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth","volume":"7","author":"Huart","year":"2012","journal-title":"PLoS One"},{"key":"2024020614011291800_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"key":"2024020614011291800_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1073\/pnas.1818798116","article-title":"Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response","volume":"116","author":"Park","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024020614011291800_bib48","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3109\/10428194.2016.1160083","article-title":"Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma","volume":"57","author":"Haery","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2024020614011291800_bib49","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1073\/pnas.1619555114","article-title":"Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth","volume":"114","author":"Hashwah","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024020614011291800_bib50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2016-05-718775","article-title":"B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma","volume":"129","author":"Dai","year":"2017","journal-title":"Blood"},{"key":"2024020614011291800_bib51","doi-asserted-by":"crossref","first-page":"e005442","DOI":"10.1136\/jitc-2022-005442","article-title":"Combining precision oncology and immunotherapy by targeting the MALT1 protease","volume":"10","author":"Mempel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2024020614011291800_bib52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tibs.2004.11.009","article-title":"Phosphorylation of NF-\u03baB and I\u03baB proteins: implications in cancer and inflammation","volume":"30","author":"Viatour","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"2024020614011291800_bib53","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.cdd.4401845","article-title":"Controlling NF-\u03baB activation in T cells by costimulatory receptors","volume":"13","author":"Schmitz","year":"2006","journal-title":"Cell Death Differ"},{"key":"2024020614011291800_bib54","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024020614011291800_bib55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"2024020614011291800_bib56","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"2024020614011291800_bib57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clml.2021.09.011","article-title":"Refractory DLBCL: challenges and treatment","volume":"22","author":"Goldfinger","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024020614011291800_bib58","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.4103\/jfmpc.jfmpc_2432_21","article-title":"Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment","volume":"11","author":"Mamgain","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"2024020614011291800_bib59","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2024020614011291800_bib60","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.2019002395","article-title":"Avadomide monotherapy in relapsed\/refractory DLBCL: safety, efficacy, and a predictive gene classifier","volume":"135","author":"Carpio","year":"2020","journal-title":"Blood"},{"key":"2024020614011291800_bib61","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"2024020614011291800_bib62","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/bloodadvances.2020003431","article-title":"Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen","volume":"5","author":"Mo","year":"2021","journal-title":"Blood Adv"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0264\/3407525\/crc-23-0264.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/2\/312\/3413418\/crc-23-0264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/2\/312\/3413418\/crc-23-0264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T09:02:03Z","timestamp":1707210123000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/2\/312\/734090\/FPFT-2216-a-Novel-Anti-lymphoma-Compound-Induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,6]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0264","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.25152470.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152473","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152497","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152485","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152467.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152491","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152479","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152467","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152500","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152512","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152506","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152482","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152470","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152494.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152509.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152494","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152512.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152488.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152506.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152488","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152497.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152476","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152491.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152509","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152476.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152500.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152503.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152485.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152482.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152503","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152473.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25152479.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7061618.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7061618","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]}}}